The Zydus Pinkathon, a prominent women’s running event, is set to return to Bengaluru on January 25, marking its eighth edition in the city after a seven-year hiatus. With an expected participation of over 5,000 women, the event aims to promote fitness and community engagement among women of all age groups and fitness levels. The event will feature various race categories, including 3 km, 5 km, and 10 km runs, as well as ultradistances of 50 km, 75 km, and 100 km, and a 100 km relay.<\/p>\n
The Bengaluru edition is being supported by the Department of Youth Empowerment and Sports, Government of Karnataka, and has received institutional backing from the Sports Authority of India and Fit India. The event is designed to encourage women to adopt regular physical activity, particularly in a city like Bengaluru, which is known for its young, working population and high-pressure lifestyles.<\/p>\n
Founded by Milind Soman in 2012, Pinkathon has positioned Bengaluru as a key city in its journey, citing the city’s strong running culture and growing focus on wellness. The event has become a significant part of the city’s fitness landscape, and its return is expected to be a major boost to the city’s running community.<\/p>\n
The Zydus Pinkathon is part of the 2025-26 nationwide season, which will also include events in Hyderabad on February 15 and Delhi on March 8. The event’s organizers aim to use the platform to promote fitness-led community engagement and encourage women to prioritize their physical and mental well-being. With its diverse range of race categories and inclusive approach, the Zydus Pinkathon is expected to be a memorable and empowering experience for all participants. Overall, the return of the Zydus Pinkathon to Bengaluru is a significant development for the city’s fitness enthusiasts and a testament to the growing importance of women’s health and wellness in India.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Zydus Pinkathon, a prominent women’s running event, is set to return to Bengaluru on January 25, marking its eighth edition in the city after a seven-year hiatus. With an expected participation of over 5,000 women, the event aims to promote fitness and community engagement among women of all age groups and fitness levels. The […]<\/p>\n","protected":false},"author":1,"featured_media":88150,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2,19],"tags":[],"class_list":["post-89854","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma","category-zydus"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89747,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/tragedy-strikes-in-bengaluru-as-26-year-old-biocon-staff-member-takes-fatal-leap-from-5th-floor-of-office-building\/","url_meta":{"origin":89854,"position":0},"title":"Tragedy strikes in Bengaluru as 26-year-old Biocon staff member takes fatal leap from 5th floor of office building.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"A 26-year-old employee of Biocon, a biopharmaceutical company, jumped to his death from the 5th floor of the company's office building in Bengaluru, India. The incident occurred on a recent day, and the police are currently investigating the circumstances surrounding the death. According to reports, the employee, whose identity has\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89869,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/27\/zydus-lifesciences-introduces-indias-first-biosimilar-version-of-nivolumab-a-global-breakthrough\/","url_meta":{"origin":89854,"position":1},"title":"Zydus Lifesciences introduces India’s first biosimilar version of Nivolumab, a global breakthrough.","author":"Team Small News","date":"January 27, 2026","format":false,"excerpt":"Zydus Lifesciences, a leading life sciences company, has launched the world's first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in the field of Immuno-Oncology. Tishtha will be available in two dosage strengths, 100\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89789,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/delhi-high-court-grants-permission-to-zydus-to-market-nivolumab-biosimilar-a-cancer-treatment-drug-in-india\/","url_meta":{"origin":89854,"position":2},"title":"Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a previous order that had restrained the launch\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89690,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/20\/zydus-lifesciences-partners-with-myriad-genetics-to-introduce-cutting-edge-cancer-diagnostic-solutions-in-india\/","url_meta":{"origin":89854,"position":3},"title":"Zydus Lifesciences Partners with Myriad Genetics to Introduce Cutting-Edge Cancer Diagnostic Solutions in India.","author":"Team Small News","date":"December 20, 2025","format":false,"excerpt":"Zydus Lifesciences Limited, a global life sciences company, has partnered with US-based Myriad Genetics to introduce advanced cancer-risk assessment and prognostic diagnostic tests in India. The exclusive agreement allows Zydus to offer Myriad's MyRisk Hereditary Cancer Test, MyChoice HRD Plus Test, and Prolaris Prostate Cancer Prognostic Test to patients, clinicians,\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89795,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/13\/the-delhi-high-court-has-granted-permission-to-zydus-to-market-a-more-affordable-biosimilar-version-of-the-cancer-medication-nivolumab-citing-public-interest\/","url_meta":{"origin":89854,"position":4},"title":"The Delhi High Court has granted permission to Zydus to market a more affordable biosimilar version of the cancer medication Nivolumab, citing public interest.","author":"Team Small News","date":"January 13, 2026","format":false,"excerpt":"The Delhi High Court has given a significant ruling in favor of Zydus, a pharmaceutical company, allowing it to sell a biosimilar version of the cancer drug Nivolumab at a lower price. Nivolumab, marketed under the brand name Opdivo by Bristol Myers Squibb, is a monoclonal antibody used to treat\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89683,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/19\/zydus-lifesciences-partners-to-introduce-diagnostic-tests-for-cancer-risk-evaluation-in-indian-market\/","url_meta":{"origin":89854,"position":5},"title":"Zydus Lifesciences Partners to Introduce Diagnostic Tests for Cancer Risk Evaluation in Indian Market","author":"Team Small News","date":"December 19, 2025","format":false,"excerpt":"Zydus Lifesciences Limited is a global life sciences company based in India that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare therapies. The company operates in the business of integrated pharmaceutical operations, offering a diverse product portfolio that includes active pharmaceutical ingredients (API),\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89854"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89854\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88150"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}